TapewireFind a company

person · Reporting owner

Pauwels Eric

Disclosed activity across 1 company

Tapewire entity
38959
SEC CIK
0001323212

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
PTC THERAPEUTICS, INC.PTCT · Entity 3803CHIEF BUSINESS OFFICERJune 10, 2026June 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

PTC THERAPEUTICS, INC.

Report date June 10, 2026 · Filed June 12, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect73,411 Ending reported balance After 2026-06-10 transaction · row 3
3 source rows · reconciled sequence

Row 1 · 2026-06-10 · Sale · Disposed 3,711 · Balance 73,411

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 25, 2026.

Row 2 · 2026-06-10 · Exercise / conversion · Acquired 17,566 · Balance 90,977

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 25, 2026.

Row 3 · 2026-06-10 · Sale · Disposed 17,566 · Balance 73,411

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 25, 2026.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.01 · Expires 2028-01-02Direct0 Reported balance After 2026-06-10 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2026-06-10 · Sale · Disposed 17,566 · Balance 0

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 25, 2026.

F2: Currently exercisable.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 25, 2026.

F2: Currently exercisable.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 08, 2025 Filed Sep 9, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 2,406 $0.00 Strike: $11.23 $0.00
Disclosure

SEC source: 0001415889-25-023986 · form4-09092025_050901.xml · derivative · entry 19

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,406 shares

Expires 2027-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025.

F10 · derivative.exercise_date: Currently exercisable.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 3,713 $0.00 Strike: $30.86 $0.00
Disclosure

SEC source: 0001415889-25-023986 · form4-09092025_050901.xml · derivative · entry 18

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,713 shares

Expires 2026-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025.

F10 · derivative.exercise_date: Currently exercisable.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 8,528 $0.00 Strike: $18.01 $0.00
Disclosure

SEC source: 0001415889-25-023986 · form4-09092025_050901.xml · derivative · entry 17

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,528 shares

Expires 2028-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025.

F10 · derivative.exercise_date: Currently exercisable.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 6,017 $0.00 Strike: $11.23 $0.00
Disclosure

SEC source: 0001415889-25-023986 · form4-09092025_050901.xml · derivative · entry 16

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,406

Underlying: Common Stock · 6,017 shares

Expires 2027-01-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025.

F10 · derivative.exercise_date: Currently exercisable.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionStock Option (Right to Buy) · Derivative 16,698 $0.00 Strike: $30.86 $0.00
Disclosure

SEC source: 0001415889-25-023986 · form4-09092025_050901.xml · derivative · entry 15

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,713

Underlying: Common Stock · 16,698 shares

Expires 2026-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025.

F10 · derivative.exercise_date: Currently exercisable.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,250 $56.86 $71,075.00
Disclosure

SEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 14

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 72,912

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025.

F9 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.50 to $57.10 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 1,250 $11.32 $14,150.00
Disclosure

SEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 13

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 74,162

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,238 $56.85 $70,380.30
Disclosure

SEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 12

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 72,912

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025.

F8 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.50 to $57.14 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 1,238 $11.32 $14,014.16
Disclosure

SEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 11

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 74,150

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 2,406 $56.92 $136,949.52
Disclosure

SEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 10

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 72,912

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025.

F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.57 to $57.45 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 2,406 $11.23 $27,019.38
Disclosure

SEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 9

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,318

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 3,713 $56.92 $211,343.96
Disclosure

SEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 8

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 72,912

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025.

F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.60 to $57.45 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 3,713 $30.86 $114,583.18
Disclosure

SEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 7

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 76,625

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 8,528 $56.92 $485,413.76
Disclosure

SEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 6

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 72,912

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025.

F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.50 to $57.38 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 8,528 $18.01 $153,589.28
Disclosure

SEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 5

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 81,440

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 6,017 $56.91 $342,427.47
Disclosure

SEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 4

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 72,912

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025.

F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.50 to $57.42 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 6,017 $11.23 $67,570.91
Disclosure

SEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 3

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 78,929

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 16,698 $56.94 $950,784.12
Disclosure

SEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 2

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 72,912

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025.

F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.59 to $57.41 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 21:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 Exercise / conversionCommon Stock 16,698 $30.86 $515,300.28
Disclosure

SEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 1

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 89,610

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025.

F2 · balance_after: Includes 272 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2025.

Read SEC document
March 17, 2025 Filed Mar 18, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 300 $58.31 $17,493.00
Disclosure

SEC source: 0001415889-25-008452 · form4-03182025_050301.xml · nonDerivative · entry 5

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 72,640

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 13, 2024.

F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $58.30 to $58.31 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 17, 2025 Filed Mar 18, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 3,340 $57.67 $192,617.80
Disclosure

SEC source: 0001415889-25-008452 · form4-03182025_050301.xml · nonDerivative · entry 4

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 72,940

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 13, 2024.

F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $57.30 to $58.26 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 17, 2025 Filed Mar 18, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,085 $56.62 $61,432.70
Disclosure

SEC source: 0001415889-25-008452 · form4-03182025_050301.xml · nonDerivative · entry 3

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 76,280

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 13, 2024.

F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.20 to $57.14 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 17, 2025 Filed Mar 18, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 2,037 $55.24 $112,523.88
Disclosure

SEC source: 0001415889-25-008452 · form4-03182025_050301.xml · nonDerivative · entry 2

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 77,365

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 13, 2024.

F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $55.00 to $55.98 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
March 14, 2025 Filed Mar 18, 2025 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 4,458 $55.19 $246,037.02
Disclosure

SEC source: 0001415889-25-008452 · form4-03182025_050301.xml · nonDerivative · entry 1

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 79,402

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 13, 2024.

F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $55.00 to $55.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
February 20, 2025 Filed Feb 21, 2025 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,567 $50.12 $78,544.31
Disclosure

SEC source: 0001415889-25-005137 · form4-02212025_050211.xml · nonDerivative · entry 2

Pauwels Eric · CIK 0001323212 · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 83,860

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 5,500 RSUs from a February 15, 2024 grant of 22,000 RSUs and the vesting of 1,150 RSUs from a February 15, 2024 grant of 2,300 RSUs.

Read SEC document
February 19, 2025 Filed Feb 21, 2025 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,378 $50.10 $69,032.29
Disclosure

SEC source: 0001415889-25-005137 · form4-02212025_050211.xml · nonDerivative · entry 1

Pauwels Eric · CIK 0001323212 · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 85,427

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 5,500 RSUs from a February 15, 2024 grant of 22,000 RSUs and the vesting of 1,150 RSUs from a February 15, 2024 grant of 2,300 RSUs.

Read SEC document
January 08, 2025 Filed Jan 10, 2025 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 2,136 $44.50 $95,052.00
Disclosure

SEC source: 0001415889-25-001294 · form4-01102025_050109.xml · nonDerivative · entry 2

Pauwels Eric · CIK 0001323212 · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 86,805

F2 · shares: Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 6, 2021 grant of 10,200 RSUs and the vesting of 4,200 RSUs from a January 7, 2022 grant of 16,800 RSUs.

Read SEC document
January 07, 2025 Filed Jan 10, 2025 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,599 $45.34 $72,498.66
Disclosure

SEC source: 0001415889-25-001294 · form4-01102025_050109.xml · nonDerivative · entry 1

Pauwels Eric · CIK 0001323212 · CHIEF EXECUTIVE OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 88,941

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,500 RSUs from a January 5, 2023 grant of 18,000 RSUs.

Read SEC document
January 03, 2025 Filed Jan 7, 2025 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 GrantStock Option (Right to Buy) · Derivative 55,000 $0.00 Strike: $46.54 $0.00
Disclosure

SEC source: 0001415889-25-001017 · form4-01072025_050105.xml · derivative · entry 2

Pauwels Eric · CIK 0001323212 · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2035-01-02

F3 · derivative.exercise_date: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026.

Read SEC document
January 03, 2025 Filed Jan 7, 2025 22:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 GrantCommon Stock 22,000 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-001017 · form4-01072025_050105.xml · nonDerivative · entry 1

Pauwels Eric · CIK 0001323212 · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,540

F1 · shares: Restricted stock units granted on January 3, 2025 that vest in four equal installments over four years, commencing on January 3, 2026.

F2 · balance_after: Includes 445 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2024, and 401 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2024.

Read SEC document
April 17, 2024 Filed Apr 19, 2024 21:20 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 787 $25.14 $19,781.25
Disclosure

SEC source: 0001415889-24-011248 · form4-04192024_050404.xml · nonDerivative · entry 1

Pauwels Eric · CIK 0001323212 · Director · CHIEF EXECUTIVE OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,694

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 2,500 RSUs from an April 16, 2020 grant of 10,000 RSUs.

Read SEC document
February 15, 2024 Filed Feb 16, 2024 22:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 GrantStock Option (Right to Buy) · Derivative 55,000 $0.00 Strike: $25.69 $0.00
Disclosure

SEC source: 0001415889-24-004162 · form4-02162024_050202.xml · derivative · entry 3

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2034-02-14

F3 · derivative.exercise_date: This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025.

Read SEC document
February 15, 2024 Filed Feb 16, 2024 22:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 GrantCommon Stock 2,300 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-004162 · form4-02162024_050202.xml · nonDerivative · entry 2

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,481

F2 · shares: Restricted stock units granted on February 15, 2024 that vest in two equal installments over two years, commencing on February 15, 2025.

Read SEC document
February 15, 2024 Filed Feb 16, 2024 22:00 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 GrantCommon Stock 22,000 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-004162 · form4-02162024_050202.xml · nonDerivative · entry 1

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,181

F1 · shares: Restricted stock units granted on February 15, 2024 that vest in four equal installments over four years, commencing on February 15, 2025.

Read SEC document
January 30, 2024 Filed Feb 1, 2024 21:16 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 366 $27.25 $9,973.79
Disclosure

SEC source: 0001415889-24-002171 · form4-02012024_090228.xml · nonDerivative · entry 1

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,181

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 1,198 RSUs from a January 29, 2020 grant of 4,790 RSUs.

Read SEC document
January 09, 2024 Filed Jan 10, 2024 21:09 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 2,065 $29.01 $59,915.56
Disclosure

SEC source: 0001415889-24-000917 · form4-01102024_090157.xml · nonDerivative · entry 2

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,547

F3 · shares: Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 6, 2021 grant of 10,200 RSUs and the vesting of 4,200 RSUs from a January 7, 2022 grant of 16,800 RSUs

Read SEC document
January 08, 2024 Filed Jan 10, 2024 21:09 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,569 $28.64 $44,936.63
Disclosure

SEC source: 0001415889-24-000917 · form4-01102024_090157.xml · nonDerivative · entry 1

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,612

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,500 RSUs from a January 5, 2023 grant of 18,000 RSUs.

F2 · balance_after: Includes 327 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2023 and 301 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2023.

Read SEC document
May 22, 2023 Filed May 23, 2023 20:05 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 100 $59.66 $5,966.00
Disclosure

SEC source: 0001415889-23-008568 · form4-05232023_080529.xml · nonDerivative · entry 3

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,553

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 13, 2022.

Read SEC document
May 22, 2023 Filed May 23, 2023 20:05 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 1,913 $58.98 $112,825.49
Disclosure

SEC source: 0001415889-23-008568 · form4-05232023_080529.xml · nonDerivative · entry 2

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,653

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 13, 2022.

F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $58.61 to $59.52 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
May 19, 2023 Filed May 23, 2023 20:05 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 6,403 $58.96 $377,490.79
Disclosure

SEC source: 0001415889-23-008568 · form4-05232023_080529.xml · nonDerivative · entry 1

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,566

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 13, 2022.

F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $58.50 to $59.42 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
May 18, 2023 Filed May 19, 2023 20:04 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 788 $58.71 $46,266.87
Disclosure

SEC source: 0001415889-23-008390 · form4-05192023_080525.xml · nonDerivative · entry 3

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 55,969

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 13, 2022.

F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $58.50 to $59.16 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
May 17, 2023 Filed May 19, 2023 20:04 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 7,248 $58.50 $424,008.00
Disclosure

SEC source: 0001415889-23-008390 · form4-05192023_080525.xml · nonDerivative · entry 2

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,757

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 13, 2022.

Read SEC document
May 17, 2023 Filed May 19, 2023 20:04 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 800 $58.52 $46,814.00
Disclosure

SEC source: 0001415889-23-008390 · form4-05192023_080525.xml · nonDerivative · entry 1

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,005

F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 13, 2022.

F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $58.50 to $58.53 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Read SEC document
April 18, 2023 Filed Apr 20, 2023 20:07 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 732 $52.04 $38,095.99
Disclosure

SEC source: 0001415889-23-006752 · form4-04202023_080433.xml · nonDerivative · entry 1

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 64,805

F1 · kind: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,500 RSUs from an April 16, 2020 grant of 10,000 RSUs.

Read SEC document
January 31, 2023 Filed Feb 2, 2023 21:21 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 375 $45.63 $17,110.50
Disclosure

SEC source: 0001415889-23-001800 · form4-02022023_090223.xml · nonDerivative · entry 1

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,537

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,197 RSUs from a January 29, 2020 grant of 4,790 RSUs.

Read SEC document
January 24, 2023 Filed Jan 26, 2023 21:23 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 359 $47.45 $17,035.02
Disclosure

SEC source: 0001415889-23-001460 · form4-01262023_090158.xml · nonDerivative · entry 1

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,912

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,155 shares of restricted stock from a January 22, 2019 grant of 4,620 shares of restricted stock.

Read SEC document
January 11, 2023 Filed Jan 12, 2023 21:35 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 571 $44.36 $25,329.33
Disclosure

SEC source: 0001415889-23-000878 · form4-01122023_090113.xml · nonDerivative · entry 2

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,271

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 4,200 RSUs from a January 7, 2022 grant of 16,800 RSUs.

Read SEC document
January 10, 2023 Filed Jan 12, 2023 21:35 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 663 $42.93 $28,464.51
Disclosure

SEC source: 0001415889-23-000878 · form4-01122023_090113.xml · nonDerivative · entry 1

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,842

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 4,200 RSUs from a January 7, 2022 grant of 16,800 RSUs.

Read SEC document
January 09, 2023 Filed Jan 11, 2023 23:12 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 SaleCommon Stock 858 $41.66 $35,741.02
Disclosure

SEC source: 0001415889-23-000835 · form4-01112023_110128.xml · nonDerivative · entry 1

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,505

F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 6, 2021 grant of 10,200 RSUs.

Read SEC document
January 05, 2023 Filed Jan 9, 2023 21:54 UTC PTC THERAPEUTICS, INC. PTCT · Entity 3803 GrantStock Option (Right to Buy) · Derivative 45,000 $0.00 Strike: $39.42 $0.00
Disclosure

SEC source: 0001415889-23-000690 · form4-01092023_090159.xml · derivative · entry 2

Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2033-01-04

F3 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.